<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962337</url>
  </required_header>
  <id_info>
    <org_study_id>FPA008-001</org_study_id>
    <secondary_id>2013-003337-15</secondary_id>
    <nct_id>NCT01962337</nct_id>
  </id_info>
  <brief_title>Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Prime Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Five Prime Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to
      assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in
      adult healthy volunteers (Parts 1 and 2) and adult subjects with active RA (Part 3).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 56 healthy volunteers will be enrolled at 1 study center in the Netherlands for
      Parts 1 and 2, and approximately 39 subjects will be enrolled at up to 6 sites in Central and
      Eastern Europe for Part 3. Dose escalations in Parts 1 and 2 will be driven by an assessment
      of the safety profile. Review of safety and PK parameters may inform decisions to add cohorts
      with intermediate dose levels in order to reach an optimal target exposure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We have discontinued development of FPA008 in RA
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and dose-limiting toxicities of FPA008 administered in healthy volunteers and RA subjects</measure>
    <time_frame>within 4-12 weeks</time_frame>
    <description>Incidence of all-grade adverse events and dose limiting toxicities (DLT) during the DLT observation period and/or study treatment periods</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1-FPA008/Placebo Randomize DoseLevels1-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion at 4 different dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-FPA008/Placebo Randomize DoseLevels1-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual Infusions at 2 different dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-FPA008 Open-Label DoseLevels 1-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FPA008</intervention_name>
    <description>Infusion</description>
    <arm_group_label>1-FPA008/Placebo Randomize DoseLevels1-4</arm_group_label>
    <arm_group_label>2-FPA008/Placebo Randomize DoseLevels1-2</arm_group_label>
    <arm_group_label>3-FPA008 Open-Label DoseLevels 1-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion</description>
    <arm_group_label>1-FPA008/Placebo Randomize DoseLevels1-4</arm_group_label>
    <arm_group_label>2-FPA008/Placebo Randomize DoseLevels1-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1 and 2:

          -  Healthy adult male and female subjects between the ages of 21-55 years inclusive.

          -  Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum of
             72 hours after each dose.

        Part 3:

          -  RA male and female subjects between the ages of 21-70 years inclusive

          -  Evidence of active RA disease

          -  Inadequate response to biologic or non-biologic DMARDs

          -  Subjects will be required to be on background therapy with methotrexate.

        Exclusion Criteria:

        Parts 1, 2 and 3:

          -  BMI &lt;18 or &gt;32 kg/m2

          -  Clinically significant findings in physical exams and laboratory tests at screening
             and/or baseline

          -  Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU
             confinement, as applicable, and for 48 hours prior to study visits.

          -  Unwilling to abstain from exercise more strenuous than walking during CRU confinement,
             as applicable, and for 48 hours prior to study visits.

        Parts 1 and 2:

          -  Use of any prescription, non-prescription, or herbal medications as well as
             supplements or vitamins within 4 weeks prior to dosing, unless approved by the
             Investigator.

          -  Smoking more than 10 cigarettes, or the equivalent, per day.

        Part 3:

          -  Current or previous history of inflammatory joint disease other than RA

          -  Evidence of extra-articular RA disease or systemic involvement

          -  Currently taking any medications other than those allowed per protocol guidelines

          -  Any surgical procedure including bone or joint surgery within 12 weeks prior to dosing

          -  Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA

          -  Neuropathies and neurovasculopathies

          -  Concomitant use of statins while on study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Lead</last_name>
    <role>Study Director</role>
    <affiliation>Five Prime Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIK-Betegápoló Irgalmas rend-Budai Irgalmasrendi Kórház/Polyclinic of the Hospitaller Brothers of St. John of God in Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Clinical Unit</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research Center</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Early Development Services</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Kliniki Chorób Wewnętrznych Szpitala Uniwersyteckiego w Krakowie</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPolina</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

